Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT
Arcutis Biotherapeutics — Technical Presentation (March 2023)
5 slides from Arcutis Biotherapeutics's technical presentation, Mar 17, 2023
Slide 1: Patient and Healthcare Provider Perspective on the Disease Burden of Seborrheic Dermatitis
Patient and Healthcare Provider Perspective on the Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey Raj Chovatiya,1 Lakshi Aldredge,2 Candrice Heath,3 Moises Acevedo,4 David H. Chu,5 Diane Hanna,5 Melissa Seal,5 Matt Zirwas6 1Northwestern University, Chica
Slide 2: Introduction and Methods
Introduction and Methods • Seborrheic dermatitis (SD) is a common chronic inflammatory skin disease with a worldwide prevalence of up to 5%1 • While SD is common, the physical and emotion burden of SD have not been well characterized • The authors developed an online survey, conducted by The Harris
Slide 3: Results
Results PATIENT DEMOGRAPHICS HCP DEMOGRAPHICS Patient-and HCP-reported SD Symptom Severity Mean age: 40 years old • 67% physicians, 24% PAs, and 10% NPs Patient-Reported Severity HCP-Reported Severity • The mean number of years in practice: 3.1 Men 55% 13% 16% 19% Women: 45% Mean number of patients
Slide 4: Results
Results Social Life and Personal Relationships Negative Impact of SD on Hygiene Perceptions Isolating Social life Personal relationships “My seborrheic dermatitis 73% of patients said SD can be 13% 13% symptoms make people think isolating and 76% reported that that I have poor hygiene” 28% 31% Embar
Slide 5: Results and Conclusions
Results and Conclusions Patient-Reported SD Impact on Work Ever Missed Work Because of SD “The symptoms of my seborrheic Symptoms “I feel I would be further along in my career dermatitis make me less likely to want to if I didn't have seborrheic dermatitis.” interact with people at work.” 3% 58% agr
Arcutis Biotherapeutics — Technical Presentation (March 2023) on 6ix